Rewrite Acquisition is Highly Positive for Intellia Therapeutics (NTLA), Continues to Position NTLA as Leader in Genome Editing - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $180.00 price target on Intellia Therapeutics (NASDAQ: NTLA), following a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
